The U.S. Food and Drug Administration has approved a new formulation of the leukemia drug CAVHANZA (nilotinib) that dissolves on the tongue, offering patients with Philadelphia chromosome positive chronic myeloid leukemia greater flexibility in managing their condition. The orally disintegrating tablet is designed to work alongside common heartburn medications, removing a significant barrier that has affected up to one quarter of patients.
Many people with Ph+ CML also take acid reducing drugs such as proton pump inhibitors or H2 antagonists. Standard nilotinib tablets can lose effectiveness when taken with these medications, forcing patients to carefully time their doses. The new formulation solves this problem by improving how the drug dissolves in the body, allowing patients to take CAVHANZA together with acid reducing agents without any timing restrictions. Clinical trials also showed the drug has no food effect, meaning it can be taken with or without meals.
For patients who struggle with swallowing pills, the orally disintegrating tablet offers another advantage. It can be taken with or without water, dissolving directly on the tongue. This is the second product from Cycle Pharmaceuticals aimed at improving treatment for Ph+ CML and marks the company’s 10th approved therapy overall. The company worked with Flex Pharma, which used its proprietary ElectroNanoSpray platform to reformulate the established second generation tyrosine kinase inhibitor to enhance its absorption and performance.
Safety Considerations and Next Steps
As with other nilotinib products, CAVHANZA carries important safety warnings. The drug can prolong the QT interval, a heart rhythm measure, and sudden deaths have been reported. Doctors should monitor patients for low potassium or magnesium levels and perform electrocardiograms at baseline, on day seven, and periodically afterward. The drug is not recommended for patients with low potassium, low magnesium, or long QT syndrome. Common side effects include rash, headache, nausea, fatigue, and diarrhea, while serious risks include bleeding in the brain and blood clotting disorders.
The approval comes with a dedicated patient support program called Cycle Vita, which will help eligible patients access the treatment. CAVHANZA is indicated for adults newly diagnosed with Ph+ CML in chronic phase and for those whose disease has progressed or who cannot tolerate other therapies. With this new option, physicians and patients now have a more flexible tool to manage both their leukemia and their other medical needs without the burden of strict scheduling around meals or heartburn medications.